Dr. Robert W. Baker

• 
  www.mihiteria.com/webapps/site/60062/58853/news/news-mo - [Cached Version]
  Published on: 1/24/2007    Last Visited: 2/11/2008  

  In one document dated October 9, 2000, Robert Baker, a senior Lilly clinical research physician, e-mailed colleagues about a meeting of an academic advisory board he had attended in Atlanta.It had "reinforced my impression that hyperglycemia remains quite a threat for olanzapine and may merit increasing even further medical attention and marketing focus on this topic".Dr Baker added: "[The board was] quite impressed by the magnitude of weight gain on olanzapine and implications for glucose."

• 
  www.VagusNerveStimulation.com/bipolar/symbyax.cfm - [Cached Version]
  Published on: 10/12/2008    Last Visited: 1/26/2008  

  "Since bipolar disorder often emerges in late adolescence or early adulthood, the high rates of response among bipolar depressed patients who had early onset suggests that Symbyax may work well in this large, well-defined population," said Robert W. Baker, M.D., Associate Medical Director, USMD Neurosciences, Eli Lilly and Company.

• 
  olanzapine.11picks.com/ - [Cached Version]
  Published on: 1/23/2007    Last Visited: 10/5/2008  

  Eli Lilly was Concerned by Zyprexa Side-Effects from 1998, The Times (London), January 23 2007 In another document, dated October 9 2000, senior Lilly research physician Robert Baker noted that an academic advisory board he belonged to was "quite impressed by the magnitude of weight gain on olanzapine and implications for glucose."

• 
  www.drugawareness.org/Archives/2ndQtr_2003/record0034.h - [Cached Version]
  Published on: 4/11/2003    Last Visited: 8/10/2005  

  Robert W. Baker, a senior clinical research scientist at Lilly, says the company has spent millions of dollars on research evaluating the diabetes question.Roughly a quarter of Zyprexa patients gain more than 25 pounds while on the medication, Lilly researchers say, and obesity is linked with diabetes.But Dr. Baker says the evidence suggests Zyprexa itself doesn't cause diabetes-related problems.He says the research suggests that the Zyprexa patients who developed diabetes probably had elevated blood-sugar levels before taking the medication.
  
  He says, however, it is still possible that antipsychotic drugs in rare cases cause some health problems.Lilly continues to evaluate evidence and discuss research with the FDA, Dr. Baker says.

• 
  Bridgeway Center, Inc. - News - Another Eli Lilly Drug... - [Cached Version]
  Published on: 4/1/2003    Last Visited: 1/2/2004  

  By combining them, "there's a synergy effect beyond what you expect" from taking the drugs separately, said Dr. Robert W. Baker, associate medical director for U.S. neurosciences at Lilly.
  
  He said Lilly studies show Symbyax is effective in easing symptoms of depression in up to 60 percent of bipolar patients without pushing them into mania, which happens as much as half the time when antidepressants alone are given.
  
  In one eight-week Lilly study, only 5 percent of patients taking Symbyax for bipolar depression swung into the manic phase, Baker said.
  
  When effective, Symbyax "lifts the depression and gets to the middle zone you're shooting for rather than breaking through into mania," he said.
  
  Zyprexa, Lilly's current best-seller, is approved for schizophrenia and acute mania in bipolar disorder.

• 
  Connects: the Mental Health and Learning Disabilities... - [Cached Version]
  Published on: 9/28/2005    Last Visited: 10/5/2005  

  "I would hope as state formularies are looking at this, they would read the paper and think carefully about any superficial conclusion that the drugs work the same," Robert Baker, director of U.S. neuroscience for Lilly, said in a Sept. 23 telephone interview.

• 
  DailyComet.com | Daily Comet | Thibodaux, LA - [Cached Version]
  Published on: 6/29/2005    Last Visited: 6/29/2005  

  Patients for whom Zyprexa is working shouldn't have to change, said Dr. Robert W. Baker, medical director for Lilly's neurosciences division.
  
  "It is not a good idea to interrupt successful anti-psychotic treatment," Baker said.

• 
  FDA approves Lilly combination drug - [Cached Version]
  Published on: 12/29/2003    Last Visited: 12/29/2003  

  By combining the two drugs in one, "there's a synergy effect beyond what you expect" from taking the two drugs separately, said Dr. Robert W. Baker, associate medical director for U.S. neurosciences at Lilly.
  
  He said Lilly studies show Symbyax is effective in easing the symptoms of depression in bipolar patients without pushing them into mania, which often happens when antidepressants alone are given.
  
  Zyprexa, Lilly's current best-seller, is approved for schizophrenia and acute mania in bipolar disorder.

• 
  Healthy Skepticism library reference details - [Cached Version]
  Published on: 2/17/2004    Last Visited: 4/19/2005  

  Robert W. Baker, a senior clinical research scientist at Lilly, says the company has spent millions of dollars on research evaluating the diabetes question.Roughly a quarter of Zyprexa patients gain more than 25 pounds while on the medication, Lilly researchers say, and obesity is linked with diabetes.But Dr. Baker says the evidence suggests Zyprexa itself doesn't cause diabetes-related problems.He says the research suggests that the Zyprexa patients who developed diabetes probably had elevated blood-sugar levels before taking the medication.

• 
  Lilly Newsroom - US Product News Releases - [Cached Version]
  Published on: 7/20/2001    Last Visited: 6/29/2004  

  "Since bipolar disorder often emerges in late adolescence or early adulthood, the high rates of response among bipolar depressed patients who had early onset suggests that Symbyax may work well in this large, well-defined population," said Robert W. Baker, M.D., associate medical director, USMD Neurosciences, Eli Lilly and Company.

Page:  1 2 3